Asabys Partners

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that can potentially restore organ function in patients with fibrotic, inflammatory, autoimmune, and degenerative diseases. The company is focusing on biologically validated pathways, such as Transforming Growth Factor β and Hepatocyte Growth Factor, and leveraging specialized capabilities in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline across multiple fibrotic conditions, end-to-end research and development expertise, a successful business development track record, and a robust investor base.

Amelia Virtual Care, mental health technology company with offices in Barcelona and Mountain View, has developed the largest and most complete virtual reality platform in mental health, allowing professionals to treat a wide range of mental health disorders from common phobias to anxiety and depression. With over 60 employees and more than 200,000 VR sessions delivered, Amelia is present worldwide being the United States its main market. The new financing and management team will boost the company’s growth in this market, strengthening its commercial activity and clinical evidence.

Cara Care is a digital gut health platform that offers an app-based treatment to help patients with chronic gastrointestinal problems. It empowers patients suffering from chronic digestive diseases to enjoy a better life. Cara Care takes digestive health beyond the pill, bringing together behavioral, microbial, and nutritional data. Cara Care has already helped 700.000+ patients around the world with software-based medical devices.

Sidekick is a patient-centric digital care platform that is scalable across a wide range of chronic illnesses. Sidekick makes healthcare more impactful, accessible, and efficient by developing and delivering digital health products that empower patients and digitize healthcare. The Sidekick platform combines an evidence-based clinical approach with behavioral economics and gamification. Sidekick's platform approach transforms healthcare experiences, with one platform that integrates multi-chronic condition management and personalized care experiences. Sidekick partners with international pharmaceutical companies, payers and healthcare providers, helping them to put the people they serve first.

Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.

INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn.

Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology.

Koa Health is digital wellbeing and therapeutics solutions combine the latest clinical research and breakthrough technologies. It delivers mental health support that is accessible, personalized, and effective across a range of conditions. The company's other products include Mindset, offered through providers as a way to facilitate private chat-based mental health support. They create digital tools and resources for mental health that encompass prevention, prediction, and treatment. It offers a library of evidence-based activities for tackling stress, sleeping better, aiding relaxation and positive thinking, and boosting self-confidence.

Sidekick is a patient-centric digital care platform that is scalable across a wide range of chronic illnesses. Sidekick makes healthcare more impactful, accessible, and efficient by developing and delivering digital health products that empower patients and digitize healthcare. The Sidekick platform combines an evidence-based clinical approach with behavioral economics and gamification. Sidekick's platform approach transforms healthcare experiences, with one platform that integrates multi-chronic condition management and personalized care experiences. Sidekick partners with international pharmaceutical companies, payers and healthcare providers, helping them to put the people they serve first.

Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.

Origo Biopharma is a biotech company, specializes in research and development of immunotherapeutic products that address health disorders related to TGF-β signaling dysfunction, among this cancer and fibrosis.

Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.

INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn.

Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).

Cara Care is a digital gut health platform that offers an app-based treatment to help patients with chronic gastrointestinal problems. It empowers patients suffering from chronic digestive diseases to enjoy a better life. Cara Care takes digestive health beyond the pill, bringing together behavioral, microbial, and nutritional data. Cara Care has already helped 700.000+ patients around the world with software-based medical devices.

Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.

Amelia Virtual Care, mental health technology company with offices in Barcelona and Mountain View, has developed the largest and most complete virtual reality platform in mental health, allowing professionals to treat a wide range of mental health disorders from common phobias to anxiety and depression. With over 60 employees and more than 200,000 VR sessions delivered, Amelia is present worldwide being the United States its main market. The new financing and management team will boost the company’s growth in this market, strengthening its commercial activity and clinical evidence.